Hologic Inc (NASDAQ:HOLX), the US-based diagnostics and medical technology leader in women’s health, is set to go private in a deal worth up to US$18.3 billion, marking one of the largest healthcare buyouts of the year.
Under a definitive agreement announced on Tuesday, Blackstone and TPG Capital will acquire all outstanding shares of Hologic for US$76 per share in cash, plus a contingent value right (CVR) worth up to US$3 per share tied to future revenue milestones in the company’s Breast Health division. That brings the total potential consideration to US$79 per share — a 46% premium to Hologic’s last closing price before deal talks emerged in May.
The transaction also includes minority investments from the Abu Dhabi Investment Authority (ADIA) and GIC, underscoring the global investor appetite for high-growth health-tech assets. Once completed, Hologic will delist from the NASDAQ and continue operating under its current brand and leadership team from its headquarters in Marlborough, Massachusetts.
Private equity takes a long-term view
The deal signals growing private-equity confidence in women’s health and diagnostic innovation — sectors that have proven resilient even as broader healthcare valuations soften.
“With their resources, expertise and commitment to women’s health, Blackstone and TPG will help accelerate our growth and enhance our ability to deliver critical medical technologies to customers and their patients around the world,” said Hologic CEO Stephen MacMillan, describing the agreement as “an exciting new chapter” for the company.
Blackstone senior managing director Ram Jagannath called Hologic “an outstanding global leader in advancing women’s health” whose technologies have had “a positive impact… for millions of patients worldwide,” while TPG co-managing partner Dr John Schilling said the firm saw “a compelling opportunity to draw upon our deep thematic expertise to support the development of next-generation solutions” in women’s healthcare.
For investors, the move highlights how private equity is positioning itself around long-term structural themes — ageing populations, early detection, and women-specific healthcare needs — where steady demand and high barriers to entry create durable value.
A premium deal with potential upside
Financially, the offer is compelling. A 46% premium gives shareholders an immediate cash windfall, while the CVR structure offers an incentive to stay invested in the company’s near-term growth trajectory.
That performance-linked component hinges on Hologic’s ability to hit revenue goals in its Breast Health business over the next two fiscal years — a segment that includes the company’s 3D mammography and biopsy systems. Should those milestones be met, shareholders could collect the full US$3 per share CVR payout.
The company’s board has unanimously approved the transaction, which is expected to close in the first half of 2026, pending shareholder and regulatory approvals. A 45-day “go-shop” period gives Hologic room to consider any superior proposals.
For the broader market, the deal is another reminder that diagnostics and imaging — once seen as low-growth niches — are now attracting some of the world’s biggest pools of capital. Blackstone and TPG have a track record of expanding healthcare platforms, and their entry could fuel further consolidation among mid-cap device and diagnostics firms.
What to watch
For Hologic shareholders, the deal offers a clean exit and possible upside — but also ends the company’s run as a listed medtech growth stock. Execution risk remains around revenue targets, regulatory approvals, and integration plans, though both sponsors have ample capital and operational experience.
For the sector, the message is clear: women’s health is no longer a niche play. It’s a cornerstone of the next wave of healthcare investment — and private capital is moving in fast.